Author Archives: Claire Monge

  • 21
    Jun 22
  • 0

Mobilité CR/DR en Immunologie

Tags : 

#Mobility CR/DR #Immunology

Le LBTI recherche un(e) chercheur(se) (CR ou DR) en mobilité pour rejoindre l’équipe ‘vecteurs colloïdaux et ingénierie thérapeutique ciblée'(https://lbti.ibcp.fr/?page_id=2012) pour renforcer des thématiques de recherche en immunologie et/ou immunité des muqueuses.

Contacter claire.monge@ibcp.fr et bernard.verrier@ibcp.fr

 

LBTI is open to the recruitment of a researcher (CR or DR) through mobility to join the team ‘colloidal vectors and targeted therapeutic engineering’ (https://lbti.ibcp.fr/?page_id=2012) to strengthen immunology and/or mucosal immunity research topics.

Contact claire.monge@ibcp.fr and bernard.verrier@ibcp.fr

  • 15
    Apr 20
  • 0

LBTI starts the formulation of promising antiviral drugs against Covid-19 for pulmonary delivery

CovidNanoMed project: “Nanoformulations of current therapeutic drug candidates against SARS-CoV-2 for pulmonary delivery”.

ANR Flash Covid-19 – PI: Bernard Verrier

https://anr.fr/fr/actualites-de-lanr/details/news/flash-anr-covid-19

The team of B. Verrier, with the help of the group of R. Terreux for bioinformatics and  a partnership with CEA and INRAE, have now started the identification of several promising antiviral candidates among a list of antiviral drugs or host targeted agents. The drugs will be loaded on a robust nanoparticle plateform to increase their potential efficacy through nasal or aerosol delivery.

Logo IBCP

© 2016 LBTI |Thème Developed By LBTI Com' - Mentions légales